Welcome to our dedicated page for Smith & Nephew SEC filings (Ticker: SNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reconstructing R&D outlays for a new robotics-assisted knee system or isolating legal reserves tied to global product recalls can make Smith & Nephew’s disclosures feel more like surgical manuals than investor reports. If you have ever Googled “Smith & Nephew insider trading Form 4 transactions” and ended up lost in exhibits, you know the problem. Stock Titan’s AI solves it by extracting plain-English takeaways from every filing the moment it hits EDGAR.
Whether you need a single metric or a full narrative, our platform links each document to the question you’re really asking—no 300-page download required:
- Quarterly pulse: The latest Smith & Nephew quarterly earnings report 10-Q filing arrives with side-by-side charts and AI commentary.
- Insider moves: Get Smith & Nephew Form 4 insider transactions real-time, plus alerts on Smith & Nephew executive stock transactions Form 4 before the market notices.
- Deep dives: Read a Smith & Nephew annual report 10-K simplified into key risks, R&D milestones, and segment revenue comparisons.
- Governance checks: The Smith & Nephew proxy statement executive compensation is distilled to pay-for-performance ratios, while every Smith & Nephew 8-K material events explained section highlights recalls, acquisitions, or leadership changes.
Our AI-powered summaries let you move from understanding Smith & Nephew SEC documents with AI to acting on them—whether you’re running discounted cash-flow models, gauging competitive threats, or seeking Smith & Nephew earnings report filing analysis before an earnings call. With real-time updates, comprehensive coverage, and jargon-free explanations, this page makes Smith & Nephew SEC filings explained simply—and quickly—so you can focus on investment decisions, not document hunts.
Smith & Nephew plc reported insider share purchases by its chief executive and several senior executives under the company’s Employee Stock Purchase Plan. Following the 2025 interim dividend paid on 7 November 2025, the plan reinvested dividends to buy Smith & Nephew American Depositary Shares on the New York Stock Exchange on 11 November 2025 at a price of $33.2936 per ADS. Participants included Chief Executive Officer Deepak Nath, who acquired 24.80817 ADS, and senior leaders Craig Gaffin, Mizanu Kebede, Paul Connolly and Scott Schaffner, who each acquired small additional ADS positions through this single transaction process.
Smith & Nephew plc filed a report showing that BlackRock, Inc. now holds a total of 7.17% of its voting rights, combining shares and financial instruments. On the date the threshold was crossed, BlackRock held 5.01% of voting rights attached to shares and 2.16% through financial instruments, representing 61,034,371 voting rights in total. Previously, BlackRock’s position was 4.95% via shares and 2.22% via financial instruments, with the overall percentage unchanged at 7.17%. The holding includes ordinary shares, American Depository Receipts and securities lending positions.
Smith & Nephew plc reported the vesting of a restricted share award for its Chief Executive Officer, Deepak Nath, granted on 29 April 2022. On 11 November 2025, 3,016 restricted shares vested, with a portion sold to meet tax obligations.
Of the vested shares, 1,240 shares were sold to cover taxes and 1,776 shares were retained. The transaction was recorded at a price of £12.573092 per share on the London Stock Exchange (XLON). The disclosure was made under the UK Market Abuse Regulation.
Smith & Nephew plc furnished a Form 6‑K containing a UK TR‑1 notice of major holdings. The notification shows BlackRock, Inc. with a total voting interest of 7.170000%, comprised of 4.950000% voting rights attached to shares and 2.220000% through financial instruments.
Total number of voting rights held in the issuer was 60,996,414. The prior notified position was 7.180000%. The financial instruments include American Depositary Receipts (869,113 voting rights; 0.100000%), securities lending (17,105,206; 2.010000%), and CFDs (936,898; 0.110000%).
Smith & Nephew plc reported routine share acquisitions by its CEO and senior executives under the Company’s Dividend Re‑Investment Plan. The purchases followed the 2025 interim dividend and were executed on 7 November 2025 on the London Stock Exchange (XLON) at £12.4048 per share.
Participants included Chief Executive Officer Deepak Nath (2,624.43651 shares), President, Sports Medicine Scott Schaffner (746.79305), President, Advanced Wound Management and Global Commercial Operations Rohit Kashyap (427.09066), President, Orthopaedics Craig Gaffin (197.25944), Chief Quality & Regulatory Affairs Officer Mizanu Kebede (4.1729), and President, Global Operations Paul Connolly (394.41542).
The transactions relate to ordinary shares of USD 0.20 each (ISIN: GB0009223206) and were disclosed under UK Market Abuse Regulation.
Smith & Nephew plc reported a manager-related share transaction under UK Market Abuse Regulation. KAGAMA Family Investments, LP, a person closely associated with Independent Non-Executive Director Garheng Kong, purchased 3,000 Smith & Nephew American Depositary Shares at $33.9773 per ADS on the New York Stock Exchange on 2025-11-06.
This is a routine disclosure of dealings by persons discharging managerial responsibilities or their closely associated persons.
Smith & Nephew plc filed a Form 6-K reporting a PDMR share purchase. Chief Corporate Strategy & Development Officer Ajay Dhankhar bought 18,460 Smith & Nephew American Depositary Shares at $32.5792 per ADS on the New York Stock Exchange on November 6, 2025.
This filing is a routine disclosure under UK Market Abuse Regulation, documenting a senior executive’s transaction in the company’s ADSs. It records an open-market purchase by a person discharging managerial responsibilities and does not reflect an issuance by the company.
Smith+Nephew (NYSE: SNN) announced that Thérèse Esperdy will join the Board as an independent Non‑Executive Director and Senior Independent Director designate effective 1 December 2025. She is expected to succeed Angie Risley as Senior Independent Director following the Company’s AGM in May 2026.
Esperdy will serve on the Nomination & Governance and Remuneration Committees. Her background includes chairing Imperial Brands plc, board service at Moody’s Corporation, and senior leadership roles at J.P. Morgan. The company noted that no disclosure obligations arise under UKLR 6.4.8 R for this appointment.
Smith+Nephew reported Q3 2025 revenue of $1,501 million, up 5.0% on an underlying basis and 6.3% reported, with a 130bps currency tailwind. Orthopaedics grew 4.1% underlying as strong US Hip Implants offset softer US Knee Implants. Sports Medicine & ENT rose 5.1% underlying, with growth outside China and VBP headwinds easing. Advanced Wound Management increased 6.0% underlying, led by double‑digit gains in Advanced Wound Bioactives.
The company reaffirmed its full‑year outlook for around 5.0% underlying revenue growth and a trading profit margin of 19.0%–20.0%. Guidance for free cash flow was raised to around $750 million (previously more than $600 million), and the $500 million share buyback was completed. Management noted an expected net tariff impact of $15–$20 million in 2025. The US grew 5.5% underlying in the quarter; Advanced Wound Bioactives rose 12.2% underlying. Capital Markets Days are set for 8 and 11 December 2025, with full‑year results on 2 March 2026.
Smith+Nephew reported third-quarter revenue of $1,501 million, up 6.3% reported and 5.0% underlying, with a 130bps foreign exchange tailwind. Growth was broad-based: Orthopaedics underlying up 4.1%, Sports Medicine & ENT up 5.1%, and Advanced Wound Management up 6.0%. The US grew 5.5% on both a reported and underlying basis.
The company reaffirmed full-year guidance for underlying revenue growth of around 5% (around 5.7% at 31 Oct FX) and a trading profit margin of 19.0%–20.0% versus 18.1% in 2024. Free cash flow guidance was raised to around $750 million, supported by working capital discipline and efficiencies under the 12‑Point Plan. A $500 million share buyback was completed on 7 October 2025.
Management noted a 2025 tariff headwind of $15–$20 million and a 2026 Group margin impact of 25–50bps from US Medicare skin substitute reimbursement changes. Capital Markets Days are scheduled for 8 and 11 December 2025, with full-year results on 2 March 2026.
FAQ
What is the current stock price of Smith & Nephew (SNN)?
What is the market cap of Smith & Nephew (SNN)?
